(19)
(11) EP 4 041 713 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
15.01.2025 Bulletin 2025/03

(45) Mention of the grant of the patent:
11.12.2024 Bulletin 2024/50

(21) Application number: 20800444.0

(22) Date of filing: 09.10.2020
(51) International Patent Classification (IPC): 
C07D 217/04(2006.01)
A61K 31/472(2006.01)
 A61P 25/08(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 217/04; A61P 25/08
(86) International application number:
PCT/US2020/055129
(87) International publication number:
WO 2021/072307 (15.04.2021 Gazette 2021/15)

(54)

SOLID STATE CRYSTALLINE FORMS OF A SELECTIVE POTASSIUM CHANNEL MODULATOR

FESTE KRISTALLINE FORMEN EINES SELEKTIVEN KALIUMKANALMODULATORS

FORMES CRISTALLINES À L'ÉTAT SOLIDE D'UN MODULATEUR SÉLECTIF DU CANAL POTASSIQUE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 10.10.2019 US 201962913574 P

(43) Date of publication of application:
17.08.2022 Bulletin 2022/33

(60) Divisional application:
24211142.5

(73) Proprietor: Xenon Pharmaceuticals Inc.
Burnaby, BC V5G 4W8 (CA)

(72) Inventors:
  • BICHLER, Paul Robert
    Fernie, British Columbia V0B 1M0 (CA)
  • CADIEUX, Jean-Jacques A.
    Burnaby, British Columbia V5A 4Z2 (CA)
  • TANDY, Matthew David
    Vancouver, British Columbia V5M 1Z3 (CA)
  • BEATCH, Gregory N.
    Vancouver, British Columbia V7W 2H8 (CA)

(74) Representative: J A Kemp LLP 
80 Turnmill Street
London EC1M 5QU
London EC1M 5QU (GB)


(56) References cited: : 
WO-A2-2008/024398
 US-A1- 2011 003 850
   
  • MINO R CAIRA ED - MONTCHAMP JEAN-LUC: "Crystalline Polymorphism of Organic Compounds", TOPICS IN CURRENT CHEMISTRY; [TOPICS IN CURRENT CHEMISTRY], SPRINGER, BERLIN, DE, vol. 198, January 1998 (1998-01-01), pages 163 - 208, XP008166276, ISSN: 0340-1022, [retrieved on 19990226], DOI: 10.1007/3-540-69178-2_5
  • STEPHEN BYRN ET AL: "Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations", PHARMACEUTICAL RESEARCH, vol. 12, no. 7, January 1995 (1995-01-01), pages 945 - 954, XP055531015, DOI: 10.1023/A:1016241927429
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).